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Darier disease is a rare autosomal dominant disease characterized by abnormal keratinization of the
epidermis, mucosa, and nails. Acitretin, an aromatic form of tretinoin, is widely prescribed in the
treatment of Darier disease. However, signiﬁcant adverse effects can occur and there have been reports
associating intestinal inﬂammation with retinoid therapy. We report the case of a 58-year-old man who
developed a small intestine perforation after 2 years of acitretin treatment. Having excluded other
common causes, we suspected that the small intestine perforation could be the result of severe
inﬂammation of small intestine due to the long-term use of acitretin. Given the signiﬁcance of this
potential morbidity, it would seem prudent to monitor acitretin treatment for treating Darier disease by
paying more attention to clinical symptoms such as abdominal pain or bloody stool.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Darier disease is a rare, autosomal dominant disease caused by a
mutation on chromosome 12q23-24, which encodes for the
sarcoplasmic/endoplasmic reticulum Ca(2þ)-adenosine triphos-
phatase type 2 isoform (SERCA2) enzyme. This condition is
characterized by abnormal keratinization of the epidermis, nails,
and mucous membrane. Typical clinical symptoms include
keratotic papules in seborrheic regions as well as ﬂexures and
distinct nail changes, with histology of acantholysis and
dyskeratosis.
Oral acitretin is the treatment of choice for generalized or severe
Darier disease,1,2 and the recommended dosage is 0.25e0.5 mg/kg/
day. Acitretin could normalize epidermal cell proliferation, differen-
tiation, and corniﬁcation. However, it has many metabolic, skeletal,
and teratogenic adverse effects, including mucocutaneous effects,
hyperlipidemia, hepatotoxicity, and skeletal anomalies. Mucocuta-
neous adverse effects include dryness of the lips, cheilitis, thinning,
redness and scaling of the skin, and hair loss. Here,we describe a case
of jejunal perforation in a 58-year-old man suffering from Darier
disease receiving oral acitretin therapy for more than 2 years.e no ﬁnancial or non-ﬁnancial
erials discussed in this article.
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Darier disease was diagnosed by skin biopsy at our clinic in a 58-
year-old man 2 years previously. Initial symptoms included
brownish, verrucous papules over the back, chest, scalp, and
inguinal and axillary areas (Figure 1) along with itchiness and foul
smell, because the condition had been left untreated for many
years. The patient weighed 75 kg and had a history of severe itching
that was not responsive to topical steroids and emollients.
Acitretin 25 mg daily and an oral antihistamine, desloratadine
5 mg every night, were prescribed for 13 months. Initially, the
itchiness decreased and skin lesions improved, but the improve-
ment gradually faded after 1 year. Therefore, the dose of acitretin
was increased to 50 mg daily for 1 month. Due to dryness of the
mouth and intolerable skin xerosis, we adjusted the dose of aci-
tretin back to 25 mg daily and maintained this dosage for another
11 months. The patient continued to experience occasional epi-
sodes of severe skin pruritus, but his symptoms showed improve-
ment most of the time.
Complete blood count, monitoring of electrolytes and lipid
proﬁle, and liver function and renal function tests were conducted
regularly (approximately every 1e2 months). Persistent elevated
triglyceride levels (TG: approximately 163e288mg/dL) were noted.
The patient was referred to the endocrinology outpatient depart-
ment for lipid control.
The patient had intermittent abdominal pain for 1 week after a
2-year-period of acitretin treatment. In the emergency department,n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Multiple brownish, verrucous papules on the patient’s (A) chest, (B) back, (C) inguinal area, and (D) nails with longitudinal ridging and subungual hyperkeratotic debris are
shown.
Figure 2 Surgical specimen revealing a small bowel tight adhesion with mesenteric
abscess and jejunal perforation.
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Laboratory data revealed mild leukocytosis (white blood
cells ¼ 10,500/mL), but there was no fever. Abdominal computed
tomography was performed which showed jejunal mesenteric le-
sions with regional adhesion and ileus. Based on a diagnosis of
intra-abdominal abscess, the patient received emergent explor-
atory laparotomy.
During the operation, jejunal perforation with mesenteric ab-
scess and small bowel tight adhesion at the upper abdomen were
found (Figure 2). Segmental resection of small bowel with primary
anastomosis was then performed. The patient was then transferred
to a surgical intensive care unit and received systemic antibiotics.
He was discharged after 37 days without any serious sequelae.
The patient returned to our clinic after discharge. We carefully
examined his complete medical and drug history and found no
relevant contributing factors for his jejunal perforation. Although
acitretin appeared to be the most likely cause, there was no direct
evidence to prove this theory. After discussing with the patient, we
stopped acitretin and prescribed oral antihistamines (desloratadine
5 mg daily and levocetirizine 5 mg daily) together with topical
steroids and adapalene gel 0.1% to relieve his symptoms.
Discussion
Perforation of the small bowel is a rare but serious condition.
Perforation from duodenal ulcers was the most common cause in
the past. Helicobacter pylori infection or prolonged use ofnonsteroidal anti-inﬂammatory drugs (NSAIDs)3 may all contribute
to perforation in the small intestine. Currently, perforation that
occurs during endoscopy is not an uncommon cause. Other causes
of perforation include infections (e.g., tuberculosis and cytomega-
lovirus), Crohn’s disease, ischemia, injury from radiation therapy,
cancer (such as lymphoma or adenocarcinoma), and swallowed
foreign bodies.
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for 2 years. After reviewing his medical history, we found that he
had been taking atorvastatin and valsartan regularly for more than
1 year. Atorvastatin and valsartan have no known adverse effects of
inﬂammatory bowel disease or bowel perforation, and are used for
lowering blood triglyceride levels and controlling hypertension,
respectively. The patient also took ambroxol, dextromethorphan,
and theophylline intermittently for more than 1 year due to
smoking-induced chronic cough and dyspnea. No other obvious life
stress or use of NSAIDs was recorded. The test for H. pylori infection
was not conducted because H. pylori is often associated with
gastrointestinal ulcers above the duodenum, unlike the ﬁndings in
our case.
In the past 2 years, the patient neither received any endoscopic
procedure nor experienced any blunt abdominal injury. During the
operation, we only found perforations on a part of the small in-
testine along with mesenteric abscess and adhesion. The pathology
of resected jejunum showed inﬂammatory ulcers with micro-
perforation (Figure 3). Yamada et al. reported a case of all-trans
retinoic acid-induced vasculitis and hemonecrosis of the ileum in a
patient with acute promyelocytic leukemia.4 However, the skin
lesions and pathology of our case did not show the characteristics
of leukocytoclastic vasculitis as described by Yamada et al.
Comparing it with clinical manifestations and pathologic ﬁndings,
we could rule out retinoic acid-induced vasculitis, uncommon in-
ﬂammatory bowel disease, underlying malignancy, or atypical
infection.
Retinoids are derivatives of vitamin A that have been shown to
normalize keratinocyte differentiation and proliferation. Acitretin
is an aromatic form of tretinoin, and is useful for controlling
extensive or severe Darier disease. A wide range of adverse ef-
fects5,6 may occur with its use, including cheilitis, xerosis, retinoid
dermatitis, dyslipidemia, desquamation, photosensitivity, paro-
nychia, pyogenic granuloma,7 and onycholysis, which usually dis-
appears when acitretin is used at lower doses or when themedicine
is withdrawn. Rare serious adverse effects, including pancreatitis,Figure 3 (A) Microscopically, the lesion showed ulceration and perforation with dense
neutrophils and lymphocytes inﬁltration over mucosa, submucosa, and muscle layers
(hematoxylin and eosin, 40). (B) There are hemorrhages and aggregations of chronic
and acute inﬂammatory cells over the muscle layer, and the serosa shows severe
peritoneal reactions (hematoxylin and eosin, 40).seizures, and cerebral pseudotumor, have also been noted. Mood
changes, depression,8,9 suicide risk, and inﬂammatory bowel dis-
ease are also controversial outcomes.
13-cis-Retinoic acid, also known as isotretinoin is a second-
generation retinoid acid that is particularly useful in severe cases
of acne such as severe cystic acne. It shows beneﬁcial activity in
pityriasis rubra pilaris, Darier disease, and keratosis palmosis.
Although data are currently limited, it is probable that isotretinoin
can cause intestinal inﬂammation. A small number of case reports
have reported the development of ischemic bowel disease (IBD)
while receiving isotretinoin therapy.10e12 Reddy et al13 reviewed 85
cases of IBD associated with isotretinoin reported to the US Food
and Drug Administration (FDA) between 1997 and 2002, and found
that the causal association with isotretinoin was considered prob-
able or highly probable in 75% of the cases. According to the sum-
mary of previous case reports,10e12 the period between isotretinoin
initiation and IBD onset is most commonly in months, although it
can range between days to a year.
The main forms of IBD are Crohn’s disease and ulcerative colitis.
Crohn’s disease can affect any part of the gastrointestinal tract, from
mouth to anus (i.e., skip lesions), althoughmost of the cases start in
the terminal ileum. By contrast, ulcerative colitis is restricted to the
colon and the rectum. Compared with Crohn’s disease, our case
showed small intestine inﬂammation restricted only to the
jejunum. Based on the sudden onset of clinical symptoms and
surgical ﬁndings, the clinician did not favor the diagnosis of IBD,
nor arranged for an endoscopic examination thereafter.
Retinoic acid can interfere with epithelial integrity and this may
predispose a patient to intestinal inﬂammation. Proposed mecha-
nisms include the following: (1) isotretinoin affects intestinal
epithelial growth and is involved in cell repair and apoptosis; (2)
isotretinoin increases T lymphocyte proliferation and gut homing
as well as altering T lymphocyte subsets predisposed to inﬂam-
mation; (3) isotretinoin causes neutrophil dysfunction, inhibition
of glycoprotein synthesis, dendritic cell activation and its effects on
plasma cell may also predispose a patient to inﬂammation.12 It is
reasonable that acitretin and isotretinoin share certain common
adverse effects. However, there have been no reports on small
bowel perforation associated with acitretin.
Hyperlipidemia occurs in certain patients on acitretin therapy. It
is regarded as amodiﬁable risk factor for cardiovascular disease due
to its inﬂuence on atherosclerosis.14 In addition, some cases may
predispose patients to acute pancreatitis. In our case, persistent
elevation in triglyceride levels was noted.
Questions still remain about whether any relationship exists
between atherosclerosis due to hyperlipidemia and IBD. Nonethe-
less, there is no direct evidence that retinoid toxicity is an addi-
tional risk factor for development of IBD, not even a case report.
Despite this ambiguity, we can consider this event from a different
viewpoint.
Small bowel perforation is a rare disease, especially in those
patients without speciﬁc etiology. Patients who have had a perfo-
rated bowel will need regular follow-up and treatment for the
underlying conditions that may have caused the perforation. In our
case, the duration of follow-up after discharge was approximately 9
months, and the patient continued with regular monthly follow-up
at our clinics. No more abdominal symptoms or signs were recor-
ded, after withdrawal of acitretin.
The common causes of small bowel perforation in our study
were pursued and excluded. A possibility of coincidence could not
be excluded, but was deemed unlikely. In addition, retinoids may
contribute to intestinal inﬂammation and the pathology of this case
also revealed severe intestinal inﬂammation. Therefore, it supports
the view that severe inﬂammation and perforation of small intes-
tine could be associated with acitretin.
Y.-H. Wang, D. Tsai / Dermatologica Sinica 32 (2014) 39e4242Conclusion
We present a case of small bowel perforation after 25 months of
oral acitretin therapy, in which the common causes were excluded.
In light of the signiﬁcance of this potentially life-threatening
adverse event, further studies are required to clarify the associa-
tion between small bowel perforation and oral acitretin therapy
and to identify the precise underlying mechanisms.
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